Erratum: Gene delivery to human sweat glands: A model for cystic fibrosis gene therapy (Gene Therapy (2006) vol. 12 (1752-1760) 10.1038/sj.gt.3302587);Gene delivery to human sweat glands: A model for cystic fibrosis gene therapy

Gene Therapy

Volumn 12, Issue 24, 2005, Pages 1752-1760

  Lee, H ^a,b   Koehler, D R ^a,c   Pang, C Y ^a,b   Levine, R H ^b   Ng, P ^d   Palmer, D J ^d   Quinton, P M ^e   Hu, J ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Basement membrane; Cftr; Gene delivery; Helper dependent adenovirus vector; Native tissue; Sweat glands

Indexed keywords

ADENOVIRUS VECTOR; CYTOKERATIN 18; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ARTICLE; BASEMENT MEMBRANE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; EPITHELIUM CELL; EX VIVO STUDY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; HELPER CELL; HUMAN; HUMAN TISSUE; ISOLATED ORGAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATOR GENE; SKIN BIOPSY; SKIN CULTURE; SUBMERGED CELL CULTURE; SWEAT GLAND;

ADENOVIRIDAE; PRIMATES; RODENTIA;

EID: 28844496372     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302905     Document Type: Erratum

References (41)

1. Quinton PM. Physiological basis of cystic fibrosis: A historical perspective. Physiol Rev 1999; 79: S3-S22.
2. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79: S23-S45.
3. Boucher RC. An overview of the pathogenesis of cystic fibrosis lung disease. Adv Drug Deliv Rev 2002; 54: 1359-1371.
4. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-951.
5. Dorin JR et al. A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction. Gene Therapy 1996; 3: 797-801.
6. Kerem B, Kerem E. The molecular basis for disease variability in cystic fibrosis. Eur J Hum Genet 1996; 4: 65-73.
7. Amaral MD. Processing of CFTR: Traversing the cellular maze - how much CFTR needs to go through to avoid cystic fibrosis? Pediatr Pulmonol 2005; 39: 479-491.
8. Albelda SM, Wiewrodt R, Zuckerman JB. Gene therapy for lung disease: hype or hope? Ann Intern Med 2000; 132: 649-660.
9. Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 1999; 79: S193-S214.
10. Koehler DR et al. Protection of Cftr knockout mice from acute lung infection by a helper-dependent adenoviral vector expressing Cftr in airway epithelia. Proc Natl Acad Sci USA 2003; 100: 15364-15369.
11. Limberis M, Anson DS, Fuller M, Parsons DW. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002; 13: 1961-1970.
12. Grubb BR et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 1994; 371: 802-806.
13. Quinton PM. The sweat gland. In: Yankaskas JR, Knowles MR (eds). Cystic Fibrosis in Adults. Lippincott-Raven: Philadelphia, 1999, pp 419-437.
14. Quinton PM, Reddy MM. Control of CFTR chloride conductance by ATP levels through non-hydrolytic binding. Nature 1992; 360: 79-81.
15. Reddy MM, Quinton PM. Control of dynamic CFTR selectivity by glutamate and ATP in epithelial cells. Nature 2003; 423: 756-760.
16. Sato K, Sato F. Methods for studying eccrine sweat gland function in vivo and in vitro. Methods Enzymol 1990; 192: 583-599.
17. Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther 2003; 8: 846-852.
18. Lee CM, Jones CJ, Kealey T. Biochemical and ultrastructural studies of human eccrine sweat glands isolated by shearing and maintained for seven days. J Cell Sci 1984; 72: 259-274.
19. Sato F, Sato K. cAMP-dependent Cl(-) channel protein (CFTR) and its mRNA are expressed in the secretory portion of human eccrine sweat gland. J Histochem Cytochem 2000; 48: 345-354.
20. Kartner N et al. Mislocalization of delta F508 CFTR in cystic fibrosis sweat gland. Nat Genet 1992; 1: 321-327.
21. Kalluri R. Basement membranes: Structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003; 3: 422-433.
22. Toietta G et al. Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter. Mol Ther 2003; 7: 649-658.
23. Chow YH et al. Targeting transgene expression to airway epithelia and submucosal glands, prominent sites of human CFTR expression. Mol Ther 2000; 2: 359-367.
24. Kozaki M et al. Immunohistochemical analysis of cytokeratin expression in dog skin. J Vet Med Sci 2001; 63: 1-4.
25. Watanabe S, Hirose M, Sato S, Takahashi H. Immunohistochemical analysis of cytokeratin expression in eccrine spiradenoma: Similarities to the transitional portions between secretory segments and coiled ducts of eccrine glands. Br J Dermatol 1994; 131: 799-807.
26. Claass A et al. Applicability of different antibodies for immunohistochemical localization of CFTR in sweat glands from healthy controls and from patients with cystic fibrosis. J Histochem Cytochem 2000; 48: 831-837.
27. Bradbury NA. Intracellular CFTR: Localization and function. Physiol Rev 1999; 79: S175-S191.
28. Hengge UR, Mirmohammadsadegh A. Adeno-associated virus expresses transgenes in hair follicles and epidermis. Mol Ther 2000; 2: 188-194.
29. Ghazizadeh S, Taichman LB. Virus-mediated gene transfer for cutaneous gene therapy. Hum Gene Ther 2000; 11: 2247-2251.
30. Li L, Hoffman RM. The feasibility of targeted selective gene therapy of the hair follicle. Nat Med 1995; 1: 705-706.
31. Lu B et al. Topical application of viral vectors for epidermal gene transfer. J Invest Dermatol 1997; 108: 803-808.
32. Domashenko A, Gupta S, Cotsarelis G. Efficient delivery of transgenes to human hair follicle progenitor cells using topical lipoplex. Nat Biotechnol 2000; 18: 420-423.
33. Huard J et al. The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers. J Virol 1996; 70: 8117-8123.
34. Weeks BS, Ramchandran RS, Hopkins JJ, Friedman HM. Herpes simplex virus type-1 and -2 pathogenesis is restricted by the epidermal basement membrane. Arch Virol 2000; 145: 385-396.
35. van Deutekom JC, Hoffman EP, Huard J. Muscle maturation: Implications for gene therapy. Mol Med Today 1998; 4: 214-220.
36. Pruchnic R et al. The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum Gene Ther 2000; 11: 521-536.
37. Saito N et al. High efficiency genetic modification of hair follicles and growing hair shafts. Proc Natl Acad Sci USA 2002; 99: 13120-13124.
38. Stenn KS et al. Dispase, a neutral protease from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. J Invest Dermatol 1989; 93: 287-290.
39. Ahrens RC et al. Use of nasal potential difference and sweat chloride as outcome measures in multicenter clinical trials in subjects with cystic fibrosis. Pediatr Pulmonol 2002; 33: 142-150.
40. Walker LC et al. Relationship between airway ion transport and a mild pulmonary disease mutation in CFTR. Am J Respir Crit Care Med 1997; 155: 1684-1689.
41. Ho LP et al. Correlation between nasal potential difference measurements, genotype and clinical condition in patients with cystic fibrosis. Eur Respir J 1997; 10: 2018-2022.